• Je něco špatně v tomto záznamu ?

Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit

P. Zadravec, L. Marečková, H. Petroková, V. Hodnik, M. Perišić Nanut, G. Anderluh, B. Štrukelj, P. Malý, A. Berlec,

. 2016 ; 11 (9) : e0162625. [pub] 20160908

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031454

Infections with shiga toxin-producing bacteria, like enterohemorrhagic Escherichia coli and Shigella dysenteriae, represent a serious medical problem. No specific and effective treatment is available for patients with these infections, creating a need for the development of new therapies. Recombinant lactic acid bacterium Lactococcus lactis was engineered to bind Shiga toxin by displaying novel designed albumin binding domains (ABD) against Shiga toxin 1 B subunit (Stx1B) on their surface. Functional recombinant Stx1B was produced in Escherichia coli and used as a target for selection of 17 different ABD variants (named S1B) from the ABD scaffold-derived high-complex combinatorial library in combination with a five-round ribosome display. Two most promising S1Bs (S1B22 and S1B26) were characterized into more details by ELISA, surface plasmon resonance and microscale thermophoresis. Addition of S1Bs changed the subcellular distribution of Stx1B, completely eliminating it from Golgi apparatus most likely by interfering with its retrograde transport. All ABD variants were successfully displayed on the surface of L. lactis by fusing to the Usp45 secretion signal and to the peptidoglycan-binding C terminus of AcmA. Binding of Stx1B by engineered lactococcal cells was confirmed using flow cytometry and whole cell ELISA. Lactic acid bacteria prepared in this study are potentially useful for the removal of Shiga toxin from human intestine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031454
003      
CZ-PrNML
005      
20171025123015.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0162625 $2 doi
035    __
$a (PubMed)27606705
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zadravec, Petra $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000, Ljubljana, Slovenia. The Chair of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000, Ljubljana, Slovenia.
245    10
$a Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit / $c P. Zadravec, L. Marečková, H. Petroková, V. Hodnik, M. Perišić Nanut, G. Anderluh, B. Štrukelj, P. Malý, A. Berlec,
520    9_
$a Infections with shiga toxin-producing bacteria, like enterohemorrhagic Escherichia coli and Shigella dysenteriae, represent a serious medical problem. No specific and effective treatment is available for patients with these infections, creating a need for the development of new therapies. Recombinant lactic acid bacterium Lactococcus lactis was engineered to bind Shiga toxin by displaying novel designed albumin binding domains (ABD) against Shiga toxin 1 B subunit (Stx1B) on their surface. Functional recombinant Stx1B was produced in Escherichia coli and used as a target for selection of 17 different ABD variants (named S1B) from the ABD scaffold-derived high-complex combinatorial library in combination with a five-round ribosome display. Two most promising S1Bs (S1B22 and S1B26) were characterized into more details by ELISA, surface plasmon resonance and microscale thermophoresis. Addition of S1Bs changed the subcellular distribution of Stx1B, completely eliminating it from Golgi apparatus most likely by interfering with its retrograde transport. All ABD variants were successfully displayed on the surface of L. lactis by fusing to the Usp45 secretion signal and to the peptidoglycan-binding C terminus of AcmA. Binding of Stx1B by engineered lactococcal cells was confirmed using flow cytometry and whole cell ELISA. Lactic acid bacteria prepared in this study are potentially useful for the removal of Shiga toxin from human intestine.
650    _2
$a albuminy $x metabolismus $7 D000418
650    _2
$a metody zobrazení buněčného povrchu $7 D061505
650    _2
$a elektroforéza v polyakrylamidovém gelu $7 D004591
650    _2
$a ELISA $7 D004797
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a imobilizované proteiny $x metabolismus $7 D055767
650    _2
$a Lactococcus lactis $x metabolismus $7 D013294
650    _2
$a vazba proteinů $7 D011485
650    _2
$a proteinové domény $7 D000072417
650    _2
$a podjednotky proteinů $x metabolismus $7 D021122
650    _2
$a transport proteinů $7 D021381
650    _2
$a rekombinantní proteiny $x metabolismus $7 D011994
650    _2
$a rekombinace genetická $x genetika $7 D011995
650    _2
$a ribozomy $x metabolismus $7 D012270
650    _2
$a sekvenční homologie aminokyselin $7 D017386
650    _2
$a shiga toxin 1 $x chemie $x metabolismus $7 D022622
650    _2
$a povrchová plasmonová rezonance $7 D020349
655    _2
$a časopisecké články $7 D016428
700    1_
$a Marečková, Lucie $u Laboratory of Ligand Engineering, Institute of Biotechnology CAS, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50, Vestec, Czech Republic.
700    1_
$a Petroková, Hana $u Laboratory of Ligand Engineering, Institute of Biotechnology CAS, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50, Vestec, Czech Republic.
700    1_
$a Hodnik, Vesna $u Department of Biology, Biotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000, Ljubljana, Slovenia. National Institute of Chemistry, Hajdrihova 19, 1000, Ljubljana, Slovenia.
700    1_
$a Perišić Nanut, Milica $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000, Ljubljana, Slovenia.
700    1_
$a Anderluh, Gregor $u Department of Biology, Biotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000, Ljubljana, Slovenia. National Institute of Chemistry, Hajdrihova 19, 1000, Ljubljana, Slovenia. $7 gn_A_00006030
700    1_
$a Štrukelj, Borut $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000, Ljubljana, Slovenia. The Chair of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000, Ljubljana, Slovenia.
700    1_
$a Malý, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology CAS, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50, Vestec, Czech Republic.
700    1_
$a Berlec, Aleš $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000, Ljubljana, Slovenia.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 9 (2016), s. e0162625
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27606705 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123057 $b ABA008
999    __
$a ok $b bmc $g 1255047 $s 992481
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 9 $d e0162625 $e 20160908 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20171025
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace